Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Change in Receivables readings, the most recent being $7.6 million for Q1 2026.

  • On a quarterly basis, Change in Receivables rose 559.92% to $7.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$16.8 million, a 169.97% decrease, with the full-year FY2025 number at -$26.1 million, down 227.73% from a year prior.
  • Change in Receivables hit $7.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from -$36.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $25.5 million in Q1 2022 to a low of -$36.1 million in Q4 2025.
  • Median Change in Receivables over the past 5 years was $3.4 million (2022), compared with a mean of $1.1 million.
  • The widest YoY moves for Change in Receivables: up 1114.19% in 2023, down 744.85% in 2023.
  • Kiniksa Pharmaceuticals International's Change in Receivables stood at $1.5 million in 2022, then soared by 1114.19% to $18.2 million in 2023, then dropped by 7.62% to $16.8 million in 2024, then tumbled by 314.71% to -$36.1 million in 2025, then skyrocketed by 121.11% to $7.6 million in 2026.
  • The last three reported values for Change in Receivables were $7.6 million (Q1 2026), -$36.1 million (Q4 2025), and $19.8 million (Q3 2025) per Business Quant data.